DK1332229T3 - Fremgangsmåde til screening af midler til at behandle overvægt - Google Patents

Fremgangsmåde til screening af midler til at behandle overvægt

Info

Publication number
DK1332229T3
DK1332229T3 DK01993389.4T DK01993389T DK1332229T3 DK 1332229 T3 DK1332229 T3 DK 1332229T3 DK 01993389 T DK01993389 T DK 01993389T DK 1332229 T3 DK1332229 T3 DK 1332229T3
Authority
DK
Denmark
Prior art keywords
obesity
activity
expression
concerns
sparc protein
Prior art date
Application number
DK01993389.4T
Other languages
English (en)
Inventor
Sophie Tartare-Deckert
Obberghen Emmanuel Van
Original Assignee
Merck Sante Sas
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante Sas, Inst Nat Sante Rech Med filed Critical Merck Sante Sas
Application granted granted Critical
Publication of DK1332229T3 publication Critical patent/DK1332229T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK01993389.4T 2000-11-10 2001-11-08 Fremgangsmåde til screening af midler til at behandle overvægt DK1332229T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0014487A FR2816633B1 (fr) 2000-11-10 2000-11-10 Methode de criblage d'agents susceptibles de traiter l'obesite
PCT/FR2001/003473 WO2002038807A1 (fr) 2000-11-10 2001-11-08 Methode de criblage d'agents susceptibles de traiter l'obesite

Publications (1)

Publication Number Publication Date
DK1332229T3 true DK1332229T3 (da) 2010-05-03

Family

ID=8856316

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01993389.4T DK1332229T3 (da) 2000-11-10 2001-11-08 Fremgangsmåde til screening af midler til at behandle overvægt

Country Status (14)

Country Link
US (1) US7651844B2 (da)
EP (1) EP1332229B1 (da)
JP (1) JP4044842B2 (da)
AT (1) ATE453726T1 (da)
AU (1) AU2304202A (da)
CA (1) CA2428492A1 (da)
CY (1) CY1110278T1 (da)
DE (1) DE60140953D1 (da)
DK (1) DK1332229T3 (da)
ES (1) ES2336649T3 (da)
FR (1) FR2816633B1 (da)
NZ (1) NZ525608A (da)
PT (1) PT1332229E (da)
WO (1) WO2002038807A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4814774B2 (ja) * 2006-12-06 2011-11-16 花王株式会社 肥満調節剤の評価方法
WO2010010383A1 (en) * 2008-07-21 2010-01-28 Isis Innovation Limited Treatment of obesity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998007435A1 (en) * 1996-08-20 1998-02-26 The Regents Of The University Of California Eye treatments using synthetic thyroid hormone compositions
WO1998020112A1 (en) * 1996-11-07 1998-05-14 The Wistar Institute Of Anatomy And Biology Sparc-deficient transgenic mice
EP0950097A2 (en) * 1996-12-27 1999-10-20 Instituto de Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy

Also Published As

Publication number Publication date
FR2816633B1 (fr) 2003-02-07
DE60140953D1 (de) 2010-02-11
JP2004517308A (ja) 2004-06-10
US7651844B2 (en) 2010-01-26
WO2002038807A1 (fr) 2002-05-16
JP4044842B2 (ja) 2008-02-06
NZ525608A (en) 2005-11-25
EP1332229A1 (fr) 2003-08-06
AU2304202A (en) 2002-05-21
FR2816633A1 (fr) 2002-05-17
EP1332229B1 (fr) 2009-12-30
PT1332229E (pt) 2010-03-10
ES2336649T3 (es) 2010-04-15
CY1110278T1 (el) 2015-01-14
CA2428492A1 (fr) 2002-05-16
ATE453726T1 (de) 2010-01-15
US20040049799A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
DK1287364T3 (da) Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
EP0895781A3 (en) Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
ATE515513T1 (de) Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten
DE60237917D1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
DK1066056T4 (da) Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, fremgangsmåde til fremstilling af jerndextranforbindelsen og anvendelse af denne forbindelse til fremstilling af et...
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
PL1694354T3 (pl) Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
UA72948C2 (uk) Заміщені похідні фенілпіперазину, фармацевтична композиція та спосіб лікування афективних або неврологічних захворювань і розладів
ATE399557T1 (de) Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
DK1397681T3 (da) Fremgangsmåde til identificering af midler til behandling af diabetes
BRPI0607684A2 (pt) composição farmacêutica, método para prevenir ou tratar distúrbios de depressão ou ansiedade, e, uso de (s)-n-[2-(1,6,7,8-tetraidro-2h-indeno[5,4-b]furan-8-il)-eti l]-propionamida
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
CY1110278T1 (el) Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια
WO2022235551A3 (en) Fc-fusion protein therapeutic for the treatment of pancreatitis
DK1133314T3 (da) Protein C til behandling af seglcellesygdom og thalassæmi